Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
Study hypothesis: Simultaneous FMC-Alemtuzumab administration followed by Alemtuzumab
maintenance therapy in patients with T-PLL is feasible, safe and efficient.